Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.

RU58841 is a controversial hair loss treatment with mixed reviews; some users report success, often in combination with other treatments like finasteride or minoxidil, while others experience side effects like chest pain. The treatment's discontinuation is speculated to be due to patent expiration and lack of profitability, despite some users continuing to use it as part of a broader regimen.

A user stopped using RU58841 after discovering their girlfriend's unplanned pregnancy, expressing concern about potential harm to the baby. Others advised consulting a doctor, waiting for health scans, and considering switching to oral finasteride or natural supplements like saw palmetto.

A user ingested RU58841 orally and experienced severe heart and breathing issues, requiring emergency medical assistance. They concluded that MV supplements is a legitimate supplier but warned of the serious side effects.

RU58841 powder is being discussed as a hair loss treatment, with concerns about its legitimacy and safety when purchased from Amazon. The conversation also mentions Minoxidil as a comparison in terms of price.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

RU58841 is discussed as a potential treatment for acne and hair loss, with users debating its effectiveness and safety compared to other treatments like finasteride, minoxidil, and dutasteride. Concerns about RU58841's side effects and lack of clinical trials are raised, while some users share their personal experiences and routines involving RU58841 for hair loss.

The conversation is about choosing between RU58841 and topical spironolactone for hair loss treatment. The user is currently using a topical solution with minoxidil, alfatradiol, and progesterone, and is concerned about side effects and effectiveness of both RU58841 and spironolactone.

A user is combining RU58841 with a topical formula containing finasteride, dutasteride, minoxidil, triamcinolone, caffeine, and other ingredients. They have just started using it and report no side effects so far.

A group buy for products to treat hair loss, such as Minoxidil, Finasteride and RU58841. Participants are interested in adding more people before ordering the next order.

RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

Treatments for hair loss, such as Minoxidil, finasteride, RU58841 and Eucapil; the legitimacy of RU58841 products; and safety concerns related to using RU58841.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

Combining topical finasteride with RU58841 for hair loss treatment. Users discuss the effectiveness and potential side effects of oral and topical finasteride.

RU58841 stopped shedding after two weeks and improved hair after eight months. Initial thinning may occur within the first month.

The user is asking if it's safe to use a glass dropper from a finished RU58841 product with a new RU58841 product and if cleaning it with water is sufficient. They are concerned about the quality of the plastic dropper that came with the new product.

The user experienced increased hair shedding after using RU58841 for two months, but found relief from scalp itchiness. Other users shared similar shedding experiences and discussed side effects like joint pain, while also mentioning the use of finasteride and minoxidil.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

RU58841 is debated for hair regrowth, with some users reporting no benefits and potential side effects, while others claim success when combined with dutasteride. Many suggest safer, well-researched treatments like finasteride and minoxidil for hair loss management.